Semaglutide is a lab-made peptide produced by genetically engineered yeast cells. It’s modeled after a natural human gut hormone called GLP-1, sharing 94% of its structure, but with three key chemical modifications that make it far more durable in the body. The active ingredient is the same whether you know it as Ozempic, Wegovy, or Rybelsus.
The Starting Point: A Human Gut Hormone
Your body naturally produces a hormone called GLP-1 (glucagon-like peptide-1) in the intestines after you eat. It signals the pancreas to release insulin, slows digestion, and communicates with the brain to reduce appetite. The problem is that natural GLP-1 breaks down in minutes, far too quickly to be useful as a medication.
Semaglutide is essentially a re-engineered version of this hormone, built to survive in the bloodstream for about a week instead of a few minutes. Scientists started with the 30-amino-acid chain of human GLP-1 and made three specific changes to create something the body can’t break down as easily.
Three Modifications That Make It Work
The first modification protects semaglutide from a specific enzyme (DPP-4) that normally chops up GLP-1 within minutes. At position 8 in the amino acid chain, the original alanine is swapped for a synthetic amino acid that this enzyme can’t recognize or cut. This single change dramatically extends the molecule’s survival time.
The second modification is the attachment of a long fatty acid chain (18 carbons long) to the amino acid at position 26, connected through a small chemical linker. This fatty chain grabs onto albumin, one of the most abundant proteins in your blood. Albumin acts like a slow-release carrier, keeping semaglutide circulating in the bloodstream for days rather than being filtered out by the kidneys. This is what makes once-weekly dosing possible, and it’s a longer fatty acid chain than the one used in liraglutide (Victoza, Saxenda), which requires daily injections.
The third change is simpler: at position 34, one amino acid (lysine) is swapped for another (arginine). This prevents the fatty acid chain from accidentally attaching in the wrong spot during manufacturing.
How Semaglutide Is Manufactured
The production process starts with baker’s yeast (Saccharomyces cerevisiae) that has been genetically programmed using recombinant DNA technology to produce a precursor version of the semaglutide peptide. The yeast cells are grown in large fermentation tanks, where they churn out this precursor protein the way they’d normally produce their own proteins.
After fermentation, the precursor is recovered from the yeast cells, isolated, and purified. Then comes the chemical modification step: the fatty acid chain and its linker are attached to the purified peptide at position 26. After that, a two-amino-acid piece is joined to the front end of the chain to complete the molecule. The final product goes through additional purification before it’s formulated into the finished drug. This multi-step process, combining biological production with precise chemical modifications, is one reason semaglutide is considered difficult to manufacture.
What’s in the Injection Besides Semaglutide
The injectable forms (Ozempic for diabetes, Wegovy for weight management) contain the same semaglutide molecule at different doses. Each milliliter of solution includes a small number of inactive ingredients that keep the drug stable and safe for injection: disodium phosphate dihydrate as a buffering agent, propylene glycol to help keep the solution stable, phenol as a preservative, and water. The solution is adjusted to a pH of about 7.4, which matches your blood’s natural pH, using tiny amounts of hydrochloric acid or sodium hydroxide.
How the Oral Tablet Differs
Rybelsus, the oral form, contains the same semaglutide molecule but faces an entirely different challenge: surviving the harsh environment of your stomach. Peptides like semaglutide are proteins, and stomach acid normally tears proteins apart before they can be absorbed.
To solve this, each Rybelsus tablet is co-formulated with 300 mg of a compound called salcaprozate sodium, or SNAC. This absorption enhancer works in two ways. It temporarily increases the permeability of the stomach lining so semaglutide can pass through into the bloodstream. It also creates a locally higher pH environment right around the tablet, essentially a small protective buffer zone that shields semaglutide from being destroyed by stomach acid. This is why Rybelsus must be taken on an empty stomach with no more than 4 ounces of plain water: food or larger volumes of liquid would dilute SNAC and prevent it from doing its job.
Why Compounded Versions Raise Concerns
The complexity of semaglutide’s manufacturing process is central to ongoing debates about compounded versions. Producing the peptide requires precise biological fermentation, multiple purification steps, and exact chemical modifications. The fatty acid chain must attach at exactly the right position, and the final molecule must fold correctly to activate GLP-1 receptors. Errors at any stage can produce a product that looks similar on paper but behaves differently in the body. The FDA has noted that semaglutide presents “demonstrable difficulties for compounding” precisely because of these manufacturing complexities.